Phase 3 Registration Trial in China for Submental Fat Reduction

Raziel Therapeutics, a pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market, announces phase 3 study initiation in China for the treatment of fat reduction in the submental area. Submental fat (SMF) reduction is the first indication for RZL-012 among many potential aesthetic focal fat reduction treatments for body shaping.

RZL-012 is an injectable lipolytic drug being developed for the reduction of unwanted submental fat („double-chin“) or fat in other body areas, in adults. The compound is injected subcutaneously into submental fat tissue in 1-2 injection sessions by trained physicians and destroys fat cells, resulting in fat volume reduction and improved appearance of the injected area.